nach oben

European Archives of Oto-Rhino-Laryngology

Erschienen in:

27.04.2023 | Head and Neck

Clinical practice guidelines for management of head and neck squamous cell carcinoma of unknown primary: an AGREE II appraisal

verfasst von: Christian Fritz, Jinggang J. Ng, Jacob Harris, Dominic J. Romeo, Aman Prasad, Alvaro Moreira, Karthik Rajasekaran

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 9/2023

Einloggen, um Zugang zu erhalten

Abstract

Importance

Squamous cell carcinoma without a known primary is an uncommon form of head and neck cancer that requires multidisciplinary collaboration for effective management.

Objective

To evaluate the quality of clinical practice guidelines (CPG) using the Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument.

Design

A systematic literature search was performed to identify CPGs pertaining to the diagnosis and treatment of head and neck squamous cell carcinoma of unknown primary (HNSCCUP). Data were abstracted from guidelines meeting inclusion criteria and appraised by four independent reviewers in the six domains of quality defined by the AGREE II.

Setting

Online database.

Participants

None.

Exposure

None.

Main outcome(s) and measure(s)

Quality domain scores and intraclass correlation coefficients (ICC) were calculated across domains to qualify inter-rater reliability.

Results

Seven guidelines met inclusion criteria. Two guidelines achieved a score of > 60% in five or more AGREE II quality domains to gain designation as ‘high’-quality content. One “average-quality” guideline authored by the ENT UK Head and Neck Society Council achieved a score of > 60% in three quality domains. The remaining four CPGs demonstrated low-quality content, with deficits most pronounced in domains 3 and 5, suggesting a lack of rigorously developed and clinically applicable information.

Conclusions and relevance

As the diagnosis and treatment of head and neck cancer continues to evolve, identification of high-quality guidelines will become increasingly important. The authors recommend consulting HNSCCUP guidelines from the National Institute for Health and Care Excellence (NICE) or the American Society of Clinical Oncology (ASCO).

Trial registration

None.

Farnebo L, Laurell G, Mäkitie A (2016) A Nordic survey on the management of head and neck CUP. Acta Otolaryngol 136(11):1159–1163. https://doi.org/10.1080/00016489.2016.1193894CrossRefPubMed

Mackenzie K, Watson M, Jankowska P, Bhide S, Simo R (2016) Investigation and management of the unknown primary with metastatic neck disease: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 130(S2):S170–S175. https://doi.org/10.1017/S0022215116000591CrossRefPubMedPubMedCentral

Mani N, George MM, Nash L, Anwar B, Homer JJ (2016) Role of 18-Fludeoxyglucose positron emission tomography-computed tomography and subsequent panendoscopy in head and neck squamous cell carcinoma of unknown primary. Laryngoscope 126(6):1354–1358. https://doi.org/10.1002/lary.25783CrossRefPubMed

Park KS, Lim HR, Jeong SH, Lee DH, Lim SC (2021) Treatment Outcomes of Patients with Head and Neck Squamous Cell Carcinoma of Unknown Primary. Chonnam Med J 57(1):58. https://doi.org/10.4068/cmj.2021.57.1.58CrossRefPubMedPubMedCentral

Strojan P, Ferlito A, Medina JE et al (2013) Contemporary management of lymph node metastases from an unknown primary to the neck: I. A review of diagnostic approaches. Head & Neck 35(1):123–132. https://doi.org/10.1002/hed.21898CrossRef

Califano J, Westra WH, Koch W et al (1999) Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. JNCI J Natl Cancer Institute 91(7):599–604. https://doi.org/10.1093/jnci/91.7.599CrossRef

de Bree R (2010) The real additional value of FDG-PET in detecting the occult primary tumour in patients with cervical lymph node metastases of unknown primary tumour. Eur Arch Otorhinolaryngol 267(11):1653–1655. https://doi.org/10.1007/s00405-010-1372-22CrossRefPubMedPubMedCentral

Mehanna H, Paleri V, West CML, Nutting C (2010) Head and neck cancer—part 1: epidemiology, presentation, and prevention. BMJ. 341:c4684. https://doi.org/10.1136/bmj.c4684CrossRefPubMed

Issing WJ, Taleban B, Tauber S (2003) Diagnosis and management of carcinoma of unknown primary in the head and neck. Eur Arch Otorhinolaryngol 260(8):436–443. https://doi.org/10.1007/s00405-003-0585-zCrossRefPubMed

10.

Strojan P, Ferlito A, Medina JE et al (2013) Contemporary management of lymph node metastases from an unknown primary to the neck: I. A review of diagnostic approaches. Head Neck 35(1):123–132. https://doi.org/10.1002/hed.21898CrossRefPubMed

11.

Regelink G, Brouwer J, de Bree R et al (2002) Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur J Nucl Med 29(8):1024–1030. https://doi.org/10.1007/s00259-002-0819-0CrossRef

12.

Civantos FJ, Vermorken JB, Shah JP et al (2020) Metastatic squamous cell carcinoma to the cervical lymph nodes from an unknown primary cancer: management in the HPV Era. Front Oncol 10:593164. https://doi.org/10.3389/fonc.2020.593164CrossRefPubMedPubMedCentral

13.

Lanzer M, Bachna-Rotter S, Graupp M et al (2015) Unknown primary of the head and neck: a long-term follow-up. J Cranio-Maxillofacial Surg 43(4):574–579. https://doi.org/10.1016/j.jcms.2015.03.004CrossRef

14.

Davis KS, Byrd JK, Mehta V et al (2014) Occult primary head and neck squamous cell carcinoma: utility of discovering primary lesions. Otolaryngol Head Neck Surg 151(2):272–278. https://doi.org/10.1177/0194599814533494CrossRefPubMedPubMedCentral

15.

Cianchetti M, Mancuso AA, Amdur RJ et al (2009) Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Laryngoscope 119(12):2348–2354. https://doi.org/10.1002/lary.20638CrossRefPubMed

16.

Grimshaw J, Freemantle N, Wallace S et al (1995) Developing and implementing clinical practice guidelines. Qual Saf Health Care 4(1):55–64. https://doi.org/10.1136/qshc.4.1.55CrossRef

17.

Brouwers MC, Kho ME, Browman GP et al (2010) AGREE II: advancing guideline development, reporting and evaluation in health care. Can Med Assoc J 182(18):E839–E842. https://doi.org/10.1503/cmaj.090449CrossRef

18.

Vlayen J, Aertgeerts B, Hannes K, Sermeus W, Ramaekers D (2005) A systematic review of appraisal tools for clinical practice guidelines: multiple similarities and one common deficit. Int J Qual Health Care 17(3):235–242. https://doi.org/10.1093/intqhc/mzi027CrossRefPubMed

19.

Fritz C, De Ravin E, Suresh N, Romeo D, Shah M, Rajasekaran K (2022) Clinical practice guidelines for management of medullary thyroid carcinoma: an AGREE II appraisal. Am J Otolaryngol 43(6):103606. https://doi.org/10.1016/j.amjoto.2022.103606CrossRefPubMed

20.

Pandya S, Suresh NV, Shah V et al (2022) A critical appraisal of clinical practice guidelines for the diagnosis and management of benign paroxysmal positional vertigo. J Laryngol Otol. https://doi.org/10.1017/S0022215122001414CrossRefPubMed

21.

Barrette LX, Connolly J, Romeo D, Ng J, Moreira AG, Rajasekaran K (2022) Quality appraisal of clinical practice guidelines for temporomandibular joint disorders using the AGREE II instrument. Oral Surg Oral Med Oral Pathol Oral Radiol 133(4):402–411. https://doi.org/10.1016/j.oooo.2021.10.021CrossRefPubMed

22.

Suresh NV, De Ravin E, Barrette LX et al (2022) Quality appraisal of clinical practice guidelines for the use of radiofrequency ablation in the treatment of thyroid nodules and cancer. Am J Otolaryngol 43(4):103508. https://doi.org/10.1016/j.amjoto.2022.103508CrossRefPubMed

23.

Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700. https://doi.org/10.1136/bmj.b2700CrossRefPubMedPubMedCentral

24.

Shin M, Prasad A, Arguelles GR et al (2021) Appraisal of clinical practice guidelines for the evaluation and management of neck masses in children. J Paediatr Child Health 57(6):803–809. https://doi.org/10.1111/jpc.15516CrossRefPubMed

25.

Romeo V, Stanzione A, Cocozza S et al (2019) A critical appraisal of the quality of head and neck cancer imaging guidelines using the AGREE II tool: a EuroAIM initiative. Cancer Med 8(1):209–215. https://doi.org/10.1002/cam4.1933CrossRefPubMed

26.

Chorath K, Garza L, Tarriela A, Luu N, Rajasekaran K, Moreira A (2021) Clinical practice guidelines on newborn hearing screening: A systematic quality appraisal using the AGREE II instrument. Int J Pediatr Otorhinolaryngol 141:110504. https://doi.org/10.1016/j.ijporl.2020.110504CrossRefPubMed

27.

Vallat R (2018) Pingouin: statistics in python. J Open Source Softw 3(31):1026. https://doi.org/10.21105/joss.01026CrossRef

28.

McHugh ML (2012) Interrater reliability: the kappa statistic. Biochem Med 22:276–282. https://doi.org/10.11613/BM.2012.031CrossRef

29.

NICE. National Institute for Health Care Excellence. Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and over. NICE guideline [NG36] 2016 [updated 06 June 2018]. https://www.nice.org.uk/guidance/ng36

30.

Maghami E, Ismaila N, Alvarez A et al (2020) Diagnosis and management of squamous cell carcinoma of unknown primary in the head and neck: ASCO guideline. J Clin Oncol 38(22):2570–2596. https://doi.org/10.1200/JCO.20.00275CrossRefPubMed

31.

Machiels JP, René Leemans C, Golusinski W et al (2021) Reprint of Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Oral Oncol. 113:105042. https://doi.org/10.1016/j.oraloncology.2020.105042CrossRefPubMed

32.

Schache A, Kerawala C, Ahmed O et al (2021) British association of head and neck oncologists (BAHNO) standards 2020. J Oral Pathol Med 50(3):262–273. https://doi.org/10.1111/jop.13161CrossRefPubMed

33.

National Comprehensive Cancer Network. Development and Update of Guidelines [Internet]. NCCN. Undated [cited 2022 Nov 7]. Available from: https://www.nccn.org/guidelines/guidelines-process/development-and- update-of-guidelines

34.

Hardman JC, Harrington K, Roques T et al (2022) Methodology for the development of National Multidisciplinary Management Recommendations using a multi-stage meta-consensus initiative. BMC Med Res Methodol 22(1):189. https://doi.org/10.1186/s12874-022-01667-wCrossRefPubMedPubMedCentral

35.

Mehta V, Johnson P, Tassler A et al (2013) A new paradigm for the diagnosis and management of unknown primary tumors of the head and neck: a role for transoral robotic surgery. Laryngoscope 123(1):146–151. https://doi.org/10.1002/lary.23562CrossRefPubMed

36.

Kang SY, Dziegielewski PT, Old MO, Ozer E (2015) Transoral robotic surgery for carcinoma of unknown primary in the head and neck. J Surg Oncol 112(7):697–701. https://doi.org/10.1002/jso.24027CrossRefPubMed

37.

Abuzeid WM, Bradford CR, Divi V (2013) Transoral robotic biopsy of the tongue base: a novel paradigm in the evaluation of unknown primary tumors of the head and neck. Head Neck 35(4):E126–E130. https://doi.org/10.1002/hed.21968CrossRefPubMed

38.

Krishnan S, Connell J, Ofo E (2017) Transoral robotic surgery base of tongue mucosectomy for head and neck cancer of unknown primary. ANZ J Surg 87(12):E281–E284. https://doi.org/10.1111/ans.13741CrossRefPubMed

39.

Jannapureddy S, Cohen C, Lau S, Beitler JJ, Siddiqui MT (2010) Assessing for primary oropharyngeal or nasopharyngeal squamous cell carcinoma from fine needle aspiration of cervical lymph node metastases. Diagn Cytopathol 38(11):795–800. https://doi.org/10.1002/dc.21293CrossRefPubMed

40.

Abi-Raad R, Prasad ML, Gilani S et al (2021) Quantitative assessment of p16 expression in FNA specimens from head and neck squamous cell carcinoma and correlation with HPV status. Cancer Cytopathol 129(5):394–404. https://doi.org/10.1002/cncy.22399CrossRefPubMed

Titel: Clinical practice guidelines for management of head and neck squamous cell carcinoma of unknown primary: an AGREE II appraisal
verfasst von: Christian Fritz
Jinggang J. Ng
Jacob Harris
Dominic J. Romeo
Aman Prasad
Alvaro Moreira
Karthik Rajasekaran
Publikationsdatum: 27.04.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Oto-Rhino-Laryngology / Ausgabe 9/2023
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-023-07997-9

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Clinical practice guidelines for management of head and neck squamous cell carcinoma of unknown primary: an AGREE II appraisal